Therapeutic Response

ER positive status confers therapeutic sensitivity to Fulvestrant in patients with Invasive Breast Carcinoma.

Statements

Source and description
Faslodex (fulvestrant) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to fulvestrant for the treatment of patients who are postmenopausal women with hormone receptor (HR)-positive advanced breast cancer with disease progression following endocrine therapy.
Faslodex (fulvestrant) [product information]. EMA. The European Medicines Agency (EMA) has authorized fulvestrant as a monotherapy for the treatment of patients who are postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer. These patients should not have been previously treated with endocrine therapy, or have had disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy.